Switch theme
Sign up to access all valuation multiples
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
1992
213
LTM Revenue $60.6M
Last FY EBITDA $6.5M
$93.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Protalix has a last 12-month revenue (LTM) of $60.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Protalix achieved revenue of $53.4M and an EBITDA of $6.5M.
Protalix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Protalix valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $60.6M | XXX | $53.4M | XXX | XXX | XXX |
| Gross Profit | $38.3M | XXX | $29.1M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $6.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 12% | XXX | XXX | XXX |
| EBIT | $12.4M | XXX | $3.9M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $11.8M | XXX | $2.9M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Protalix's stock price is $2.
Protalix has current market cap of $123M, and EV of $93.9M.
See Protalix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $93.9M | $123M | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Protalix has market cap of $123M and EV of $93.9M.
Protalix's trades at 1.8x EV/Revenue multiple, and 14.4x EV/EBITDA.
Equity research analysts estimate Protalix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Protalix has a P/E ratio of 10.4x.
See valuation multiples for Protalix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $123M | XXX | $123M | XXX | XXX | XXX |
| EV (current) | $93.9M | XXX | $93.9M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 14.4x | XXX | XXX | XXX |
| EV/EBIT | 7.6x | XXX | 24.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.4x | XXX | 42.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 12.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProtalix's last 12 month revenue growth is 47%
Protalix's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Protalix's rule of 40 is 67% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Protalix's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Protalix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 47% | XXX | 47% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 67% | XXX | 60% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Protalix acquired XXX companies to date.
Last acquisition by Protalix was XXXXXXXX, XXXXX XXXXX XXXXXX . Protalix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Protalix founded? | Protalix was founded in 1992. |
| Where is Protalix headquartered? | Protalix is headquartered in United States of America. |
| How many employees does Protalix have? | As of today, Protalix has 213 employees. |
| Who is the CEO of Protalix? | Protalix's CEO is Mr. Dror Bashan. |
| Is Protalix publicy listed? | Yes, Protalix is a public company listed on ASE. |
| What is the stock symbol of Protalix? | Protalix trades under PLX ticker. |
| When did Protalix go public? | Protalix went public in 2007. |
| Who are competitors of Protalix? | Similar companies to Protalix include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Protalix? | Protalix's current market cap is $123M |
| What is the current revenue of Protalix? | Protalix's last 12 months revenue is $60.6M. |
| What is the current revenue growth of Protalix? | Protalix revenue growth (NTM/LTM) is 47%. |
| What is the current EV/Revenue multiple of Protalix? | Current revenue multiple of Protalix is 1.5x. |
| Is Protalix profitable? | Yes, Protalix is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
